Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Inclusion Criteria

• •Heterozygote or homozygote of HLA-A\*2402 allele
• •Inoperable or recurrent pancreatic cancer with or without any prior therapy
• •Difficult to continue the prior therapy due to treatment-related toxicities
• •ECOG performance status 0-2
• •Evaluable primary or metastatic lesion with RECIST criteria
• •Clearance period from prior therapy more than 4 weeks
• •Life expectancy more than 3 months
• •Laboratory values as follows 2,000/μL\<WBC\<15,000/μL Platelet count\>100,000/μL AST\<150IU/L ALT\<150IU/L Total bilirubin\<3.0mg/dl Serum creatinine\<3.0mg/dl